^
Association details:
| Biomarker: | ALK A348D |
|---|---|
| Cancer: | Leukemia |
| Drug: | GSK 1838705A (IGF-1R inhibitor, Insulin receptor antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Therapeutically targetable ALK mutations in leukemia
Excerpt:
GSK1838705A...was also highly potent in inhibiting growth of ALK-transformed cell lines with IC50s of 18 nM and 2nM for the A348D and F856S cells respectively.
DOI:
https://dx.doi.org/10.1158%2F0008-5472.CAN-14-1576
